Guberina N, Pöttgen C, Schuler M, et al. - Researchers assessed the long-term survival of cT4 cN0/1 cM0 non-small-cell lung-cancer (NSCLC) patients receiving induction chemotherapy and concurrent radiochemotherapy prior to surgery. Participants had were sonsecutive patients with confirmed NSCLC (cT4 cN0/1 cM0) managed with neoadjuvant chemotherapy, concurrent radiochemotherapy (RT/CTx) (45–46 Gy) and surgical resection between 2000 and 2015. Overall survival was assessed as the primary endpoint. Findings demonstrated that this trimodality schedule was highly effective in patients with cT4 cN0/1 cM0 NSCLC and afforded excellent local control rates. Taking into account the annual mortality rate past 8 years of survival as an intercurrent death rate because of comorbidity, this treatment schedule was shown to attenuate annual mortality to background even in the first 5 years following therapy.